Test Code LAB000 - Enter Specimen type, Source, and Test Name Reanalysis of Acute Myeloid Leukemia 4- or 11- Gene Panels, Additional Genes
Additional Codes
Mayo test code: NGSFX
Specimen Required
No additional specimen is required. This is a bioinformatics review of additional gene regions not analyzed in the previously ordered NGAMT / Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next-Generation Sequencing or NGAML / Acute Myeloid Leukemia, 11-Gene Panel. Call 800-533-1710 for assistance with ordering.
Forms
1. Hematopathology Patient Information (T676)
2. If not ordering electronically, complete, print, and send an Hematopathology/Cytogenetics Test Request (T726) with the specimen.
Useful For
Comprehensive reanalysis of a larger set of genes/gene regions when a more targeted gene panel was previously performed in this laboratory
Evaluation of known or suspected hematologic neoplasms, specifically of myeloid origin (eg, acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelodysplastic/myeloproliferative neoplasm, unexplained cytopenias) at the time of diagnosis or possibly disease relapse, to help determine diagnostic classification and provide prognostic or therapeutic information for helping guide clinical management
Determine the presence of new clinically important gene mutation changes at relapse
Testing Algorithm
Only orderable as a reflex. Reflex testing is available upon request within 6 months of original NGAMT / Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next Generation Sequencing, Varies or NGAML / Acute Myeloid Leukemia, 11-Gene Panel, Varies sample submission.
This is a bioinformatics and variant review only for the added gene regions.
For a list of genes and exons targeted by this test see Targeted Genes Interrogated by Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing.
Special Instructions
Method Name
Only orderable as a reflex. For more information, see:
-NGAMT / Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53) Next-Generation Sequencing, Varies
-NGAML / Acute Myeloid Leukemia, 11-Gene Panel, Varies.
Next-Generation Sequencing (NGS)
Reporting Name
Reanalysis, AML 4 or 11 Gene PanelSpecimen Type
VariesSpecimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Varies | 14 days |
Reference Values
Only orderable as a reflex. For more information, see:
-NGAMT / Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next-Generation Sequencing, Varies
-NGAML / Acute Myeloid Leukemia, 11-Gene Panel, Varies.
Day(s) Performed
Monday through Friday
Report Available
16 to 21 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81450
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
NGSFX | Reanalysis, AML 4 or 11 Gene Panel | 99961-5 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
MP043 | Specimen Type | 31208-2 |
NFXID | Diagnosis/Indication | 29308-4 |
601695 | NGSFX Result | No LOINC Needed |
601687 | Pathogenic Mutations Detected | 82939-0 |
601686 | Interpretation | 69047-9 |
601688 | Clinical Trials | 82786-5 |
601689 | Variants of Unknown Significance | 93367-1 |
601690 | Additional Notes | 48767-8 |
601691 | Method Summary | 85069-3 |
601692 | Disclaimer | 62364-5 |
601693 | NGSFX Panel Gene List | 36908-2 |
601694 | Reviewed By: | 18771-6 |